[A20-13] Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V

Last updated 15.05.2020

Project no.:
A20-13

Commission:
Commission awarded on 14.02.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication/Intervention:

Treatment-naive adults with metastatic non-small cell lung cancer with activating EGFR mutations

Result of dossier assessment:

EGFR mutations Del19 or L858R: hint of lesser benefit versus appropriate comparator therapy; other EGFR mutations: added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.